Items tagged with Hepatitis C
Report shows UNITAID’s approach vital to remove market barriers so millions can have equitable access to new treatments for infectious diseases
On 14-15 January 2016 in Vilnius, Lithuania, the European Union Joint Action on HIV and Co-infection Prevention and Harm Reduction (HA-REACT) held its first Partnership Forum to kick off activities. HA-REACT addresses existing gaps in the prevention of HIV and other co-infections, especially tuberculosis and viral hepatitis, among people who inject drugs. This is a three-year project which was launched in late 2015 with core funding from the European Union (EU), and is being implemented by 23 partners in 18 EU Member States. Twelve collaborating partners are contributing additional expertise, among them the European Centre for Disease Prevention and Control and the European Monitoring Centre for Drugs and Drug Addiction.
Groundbreaking pledge of United Nations agencies to end HIV, TB and viral hepatitis epidemics in Europe at high-level meeting on ending TB (post)
For the first time, 14 United Nations agencies have joined forces to end the epidemics of HIV, tuberculosis (TB) and viral hepatitis – Europe’s deadliest communicable diseases. The commitment was demonstrated with the launch of the first-ever United Nations Common Position on Ending HIV, TB and Viral Hepatitis through Intersectoral Collaboration in the WHO European Region.
Civil society reaction to the European Commission Staff Working Document on HIV/AIDS, TB and viral hepatitis (post)
Weak signals of political commitment
UNITAID approves grants of $160 million (post with simple image)
Breakthrough new medicines for drug-resistant TB to be made available for low- and middle-income countries as part of $160 million of new grants funded by UNITAID.
HIV i-Base/TAG: 2014 Pipeline Report (post with simple image)
Latest annual review on pipeline drugs for adults and children, strategies for cure and prevention for HIV, HCV, TB and vaccine research.
Report: Global State of Harm Reduction 2014 (post with simple image)
The report includes the latest estimates around the response to drug-related HIV, viral hepatitis and tuberculosis.
WHO moves to improve access to lifesaving medicines for hepatitis C, drug-resistant TB and cancers (post with simple image)
New WHO Model List of Essential Medicines published; After about 45 years of scarce innovation for TB medicines, 5 new products are included in the List. Four of these, including bedaquiline and delamanid, target multidrug-resistant TB.
The Medicines Patent Pool releases independent feasibility studies on hepatitis C and tuberculosis (post with simple image)
As part of its ongoing consultation processes on the possibility of the Medicines Patent Pool (MPP) expanding into other disease areas, the organisation has published independent feasibility studies exploring the case for potential entry into hepatitis C and tuberculosis.
HIV i-Base/TAG: 2015 Pipeline Report (post with simple image)
Latest annual review on HIV, HCV and TB drugs, diagnostics, vaccines, preventive technologies, research toward a cure, and immune-based and gene therapies in development.
Page 1 of 2 · Total posts: 01 2 Last→